WallStreetZenWallStreetZen

NASDAQ: GOSS
Gossamer Bio Inc Stock Forecast, Predictions & Price Target

Analyst price target for GOSS

Based on 5 analysts offering 12 month price targets for Gossamer Bio Inc.
Min Forecast
$4.00+410.2%
Avg Forecast
$8.60+996.94%
Max Forecast
$15.00+1,813.27%

Should I buy or sell GOSS stock?

Based on 5 analysts offering ratings for Gossamer Bio Inc.
Strong Buy
Strong Buy
2 analysts 40%
Buy
3 analysts 60%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their GOSS stock forecasts and price targets.

GOSS stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-04-05
lockedlocked$00.00+00.00%2024-03-27
lockedlocked$00.00+00.00%2024-03-06
lockedlocked$00.00+00.00%2024-03-06
lockedlocked$00.00+00.00%2024-03-06

1 of 1

Forecast return on equity

Is GOSS forecast to generate an efficient return?
Company
N/A
Industry
N/A
Market
36%

Forecast return on assets

Is GOSS forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

GOSS revenue forecast

What is GOSS's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$13.7M
Avg 2 year Forecast
$71.6M
Avg 3 year Forecast
$163.3M

GOSS vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
GOSS$0.78$8.60+996.94%Strong Buy
OMER$3.05N/AN/A
KOD$3.36$3.33-0.80%Strong Sell
AEON$4.66$18.00+286.27%Buy
DRTS$2.56$8.00+212.50%Strong Buy

Gossamer Bio Stock Forecast FAQ

Is Gossamer Bio Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 5 Wall Street analysts covering (NASDAQ: GOSS) stock is to Strong Buy GOSS stock.

Out of 5 analysts, 2 (40%) are recommending GOSS as a Strong Buy, 3 (60%) are recommending GOSS as a Buy, 0 (0%) are recommending GOSS as a Hold, 0 (0%) are recommending GOSS as a Sell, and 0 (0%) are recommending GOSS as a Strong Sell.

If you're new to stock investing, here's how to buy Gossamer Bio stock.

What is GOSS's revenue growth forecast for 2025-2027?

(NASDAQ: GOSS) Gossamer Bio's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.03%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.06%.

Gossamer Bio's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast GOSS's revenue for 2025 to be $3,090,476,825, with the lowest GOSS revenue forecast at $3,090,476,825, and the highest GOSS revenue forecast at $3,090,476,825. On average, 3 Wall Street analysts forecast GOSS's revenue for 2026 to be $16,143,342,557, with the lowest GOSS revenue forecast at $6,226,070,100, and the highest GOSS revenue forecast at $34,647,177,778.

In 2027, GOSS is forecast to generate $36,843,446,564 in revenue, with the lowest revenue forecast at $7,259,236,805 and the highest revenue forecast at $69,028,168,500.

What is GOSS's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: GOSS) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is GOSS's Price Target?

According to 5 Wall Street analysts that have issued a 1 year GOSS price target, the average GOSS price target is $8.60, with the highest GOSS stock price forecast at $15.00 and the lowest GOSS stock price forecast at $4.00.

On average, Wall Street analysts predict that Gossamer Bio's share price could reach $8.60 by Apr 5, 2025. The average Gossamer Bio stock price prediction forecasts a potential upside of 996.94% from the current GOSS share price of $0.78.

What is GOSS's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: GOSS) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.